Table 1.
Results for H3255 cells under gefitinib treatment
| Compound | IC50 | clow | cup |  |
v |
| 17AAG | 0.0275 | 0.0237 | 0.0321 | 0.0901 | 0.0304 |
| Gefitinib | 0.0059 | 0.005 | 0.007 | 0.0858 | 0.0242 |
| Purvalanol | 5.689 | 3.850 | 8.406 | 0.1437 | 0.1618 |
| Rapamycin | 5.957 | 0.0267 | 1328 | 0.0815 | 2.183 |
| SU11274 | NA | NA | NA | 0.2413 | NA |
| UO126 | 8.414 | 7.218 | 9.808 | 0.1727 | 0.0518 |
| VX680 | 2.692 | 0.9192 | 7.881 | 0.1226 | 0.7816 |
Results of the dose-response experiment for the EGFR-mutant H3255 NSCLC cell line treated with small molecule compounds 17AAG, purvalanol, SU11274, gefitinib, rapamycin, VX680 and U0126. The lowest IC50 value (first column) reveals strong activity of gefitinib, whereas the NA values indicate that the sample is resistant to SU11274 treatment and no IC50 value was calculated. The columns clow and cup show the 95% confidence interval for the IC50 values. The maximum of the standard deviations of the measurements is given in the column , whereas in the last column, v denotes the coefficient of variation of the IC50 values.